Efficacy and Safety Study of Biweekly Docetaxel and DeGramont Regimen in First-Line Treatment of Unresectable or Metastatic Gastric Adenocarcinoma - Related Studies

Efficacy and Safety Study of Biweekly Docetaxel and DeGramont Regimen in First-Line Treatment of Unresectable or Metastatic Gastric Adenocarcinoma (DaeMon)

This study is currently recruiting participants.

Verified March 2012 by Sixth Affiliated Hospital, Sun Yat-sen University

Study NCT01567618 Information provided by Sixth Affiliated Hospital, Sun Yat-sen University

First Received on March 27, 2012. Last Updated on March 28, 2012 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Gastric Adenocarcinoma

Additional conditions recognized in this trial

Adenocarcinoma
Adenocarcinoma, Mucinous
Stomach Neoplasms

More general conditions related to this trial

Carcinoma
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Cystic, Mucinous, and Serous
Neoplasms, Glandular and Epithelial
Stomach Diseases

Interventions listed in this trial

Docetaxel
Fluorouracil

More general drug interventions related to this trial

Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

Sponsors listed in this trial

Sixth Affiliated Hospital, Sun Yat-sen University